Commentaries

14 June 2018

'Towards a cure for Haemophilia'

Towards a cure for Haemophilia.pngA report by Senior Partner, Mark Watling.


Click thumbnail to download

06 June 2018

Senior Partner, Louise Whitley, reports on DIA Europe 2018

DIA Europe 2018.pngSenior Partner, Louise Whitley, reports on DIA Europe 2018.


Click thumbnail to download

10 April 2018

Richard Bax reports on Superbugs and Superdrugs 2018

Superbugs and Superdrugs 2018 - 10 April 2018.pngInfectious Diseases Expert, Richard Bax, reports on Superbugs and Superdrugs 2018.


Click thumbnail to download

05 April 2018

Risk Management in Drug Development

Risk Management in Drug Development - April 2018Senior Partner and PV Expert, Andy Blackman, reports on Risk Management in Drug Development.


Click thumbnail to download

31 January 2018

FutureHealth 2018

FutureHealthAs a member of the FutureHealth Advisory Board, TranScrip Senior Partner, Ed Currie, attended the inaugural conference in Basel on 26th January 2018.


Click thumbnail to download

19 December 2017

Genesis 2017 – The Pathway to Patient Centricity

Genesis 2017TranScrip attended the OneNucleus Genesis 2017 conference in London on 14th December. Senior Partner, Ed Currie, chaired a panel in the main session entitled “The Pathway to Patient Centricity”.


Click thumbnail to download

30 November 2017

ESOT 2017 Highlights

ESOT 2017The 18th Congress of the European Society for Organ Transplantation (ESOT) was held from 24-27 September 2017 at the Centre de Convencions Internacional de Barcelona (CCIB). TranScrip’s Senior Partner, Louise Whitley, reports on the highlights of ESOT 2017.


Click thumbnail to download

23 October 2017

Reference Safety Information - Are You Up to Date?

Refernce Safety InformationThis is a hot GCP topic and Balall Naeem, an Inspector from MHRA, has been blogging on the issue for MHRA over the last two years. At the recent QPPV forum (DIA) Esteban Herrero-Martinez, Director Regulatory Policy and Intelligence, Abbvie gave a talk on the challenges of the Clinical Trial Reference Safety Information (RSI) from an industry QPPV perspective.


Click thumbnail to download

17 October 2017

ERS 2017 Asthma Back in Focus

ERS 2017At the European Respiratory Society (ERS) Congress September 9 – 12, Milan, there was a renewed interest in asthma, with several new approaches to the treatment of severe asthma being presented. This interest was sparked by new data and events in the asthma space.


Click thumbnail to download

19 September 2017

ESMO 2017 Facts and Figures

ESMO 2017TranScrip Senior Partners, Linda Summerton, Paul Branthwaite and Ed Currie report on the ESMO (European Society for Medical Oncology) conference in Madrid, 8-12 September 2017.


Click thumbnail to download

07 September 2017

Medical Affairs in TranScrip

Medical Affairs in TranScripTranScrip’s Medical Affairs team is experienced at conducting and facilitating two-way scientific communications.

TranScrip are unique as an agency in that they provide both strategic and tactical support for medical affairs activities, working closely with clinical development, marketing, sales and market access teams to manage a spectrum of activities from late stage clinical development, through to pre-launch and post marketing periods.


Click thumbnail to download

15 August 2017

Challenges of Programmes for Provision of Unlicensed Medicines Outside Clinical Trials

pic 4.pngTranScrip's Senior Partners, Bob Milsted and Edward Currie, report on 'Challenges of Programmes for Provision of Unlicensed Medicines Outside Clinical Trials'.


Click thumbnail to download

24 July 2017

Mandar Kelkar presents on 'Efficiency Gain in Business Models for Global Pharmacovigilance: - Automation and Burying the Silos'

Mandar PVPresented by Mandar Kelkar at the 9th International Conference and Exhibition on Pharmacovigilance and Drug Safety on 17-18 July in Munich.


Click thumbnail to view

24 July 2017

Flic Gabbay presents on 'Pharmacovigilance in 2020 - Future Horizons and Efficiencies in Data Acquisition, Evaluation and Risk Management'

Flic PV 2020Presented by Flic Gabbay at the 9th International Conference and Exhibition on Pharmacovigilance and Drug Safety on 17-18 July in Munich.


Click thumbnail to view

15 June 2017

Why Pharma should pay attention to Devices & Diagnostics

Ed ArticleTranScrip's Senior Partner, Edward Currie, reports on 'Why Pharma should pay attention to Devices & Diagnostics'.


Click thumbnail to download

30 May 2017

Flic Gabbay presents on 'Future Horizons and Efficiencies in Data Acquisition, Evaluation and Risk Management'

Flic PVPresented by TranScrip's Managing Partner, Flic Gabbay at the 3rd Annual International Conference and Exhibition in Pharmacovigilance, Regulatory Affairs, Risk Management and Clinical Trials in London on 25th May 2017.


Click thumbnail to view

11 May 2017

Meet the CEO fighting Cancer with Mycobacteria

Untitled.pngTranScrip's Senior Partner, Linda Summerton, who serves as CEO for Immodulon Therapeutics Ltd. as part of their virtual team, talks about the excitement and the challenges of steering a promising new cancer treatment through to registration for needy patients.


Click thumbnail to view

01 March 2017

Future Horizons and Efficiencies in Data Acquisition, Evaluation and Risk Management

IntraScience - 12th PV Slides_Final_01 - Copy (640x480) (140x105).jpgPresented by Ennis Lee at the 12th Pharmacovigilance 2017 Conference, 22nd & 23rd February 2017, London.


Click thumbnail to view

28 February 2017

Richard Bax Presents to the Danish Parliament, 25th January 2017

Richard Bax Presents to Danish ParliamentRichard Bax was invited as an honoured guest to a meeting on “Non-Antibiotics as Resistance Breakers to Combat Antibiotic Resistant Microorganisms”.


Click thumbnail to download

 

 

 

07 December 2016

Funding a Biopharma Without Licensing

Untitled.png"Funding a Biopharma Without Licensing" Presented at Genesis 2016, London by Linda Summerton, Senior Partner at TranScrip and CEO of Immodulon.


Click thumbnail to download

02 December 2016

The Case for Small Pharma: A Q&A With Immodulon’s Linda Summerton

Untitled.pngLinda Summerton, Senior Partner at TranScrip and CEO of Immodulon sets out the case for small pharma in this Q&A with Biotech Investing  News. The piece looks at the advantages of investing in small pharma; the challenges being faced by the sector for 2017; and why small pharma is critical to driving growth and innovation in the UK.


Click thumbnail to view

 

 

06 October 2016

Benefits and Challenges of Different Drug Safety and PV Business Models: Pilot study to understand Best Practice and innovative methods

Benefits and Challenges of Different Drug Safety and PV Business Models_front page.jpg

Presented by Flic Gabbay at the 3rd Annual Risk Management and Pharmacovigilance Summit, 27th - 29th September 2016, Vienna.


Click thumbnail to download

 

 

 

 

 

 

14 July 2016

Evolving Risk-Management Requirements in Early Development

Evolving Risk-Management Requirements in Early Development - One Nucleus.pngEvolving Risk-Management Requirements in Early Development - presented by TranScrip's Mark Watling, Chris Brearley and Ennis Lee at the One Nucleus Summer Social Event, 13th July 2016.

  • Getting the most out of Early Phase Development - by Mark Watling
  • Issues a company must ensure are addressed before going into man - by Chris Brearley
  • Ensuring compliance with changing strategies and regulations - by Ennis Lee


    Click thumbnail to download

13 July 2016

Early Clinical Development - Part 1

Early Clinical Development – Watch TranScrip's Flic Gabbay interview Chris Brearley as the first part of TranScrip's Early Clinical Development webcast series.


Click thumbnail to view

07 July 2016

Brexit and Regulatory Approval for Drugs in Europe - What Happens Now?

Q and A -Brexit and Regulatory Approval for Drugs in Europe - What Happens Now_07Jul2016_FRONT PAGE.jpg7th July 2016: Following the UK's European Union (EU) referendum, TranScrip has received many questions on what the impact is likely to be for pharmaceutical and biotech companies on the development and approval of future drugs. The following summarises TranScrip’s responses to these questions.


Click thumbnail to download